Prothrombin complex concentrates for clinical use.
Prothrombin complex concentrates prepared for clinical use are reviewed with emphasis on frequently observed adverse reactions such as viral hepatitis and thromboembolic complications. Preparation procedures and quality control are described briefly, and the use of these concentrates in the treatment of hemophilia A patients who develop factor VIII inhibitors is also described. The causes of and methods for the detection of potential thrombogenicity are discussed and suggestions which may result in a safer product are made.
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D005164:Factor IX / Q000009:adverse effects; D015949:Factor IXa; D005169:Factor VIII / Q000037:antagonists & inhibitors; D005170:Factor X / Q000009:adverse effects; D015951:Factor Xa; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006487:Hemostasis; D006509:Hepatitis B / Q000209:etiology; D006526:Hepatitis C / Q000209:etiology; D006801:Humans; D010314:Partial Thromboplastin Time; D011516:Prothrombin / Q000009:adverse effects; D011786:Quality Control; D011817:Rabbits; D013918:Thrombin Time; D065227:Transfusion Reaction
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; C025337:Factor IIa; D015949:Factor IXa; D015951:Factor Xa